| **Study** | **Year** | **Variables Assessed** | **Strength of Association (Measure of AssociationΩ)** |
| --- | --- | --- | --- |
|  |  |  | **BMI** | **BaselineCD4 Count cells/mm3** | **Clinical Staging** | **Hb** | **Age** | **HIV–1RNA Plasma Concentration** | **Sex** | **Others** |
| **Hazard Ratio (HR)** |  |  |  |  |  |  |  |  |  |
| **Sub-Saharan Africa** |  |  |  |  |  |  |  |  |  |
| Alemu | 2010 | Age, Sex, CD4, Clinical staging, Hb, Weight, CTX prophylaxis, facility | - | - | 1Real-case model:Stage 1/2 1.00(HR)Stage 4 5.13(HR)Worst-case model:Stage 1/2 1.00(HR)Stage 4 3.69(HR) | 1Real-case model:<=10 1.00(HR)>10 0.39(HR)Worst-case model:<=10 1.00(HR)>10 0.64(HR) | - | - | - | CTX useReal-case model:Absent 1.00(HR)Present 0.14(HR)Worst-case model:Absent 1.00(HR)Present 0.38(HR)Baseline weight (kg)Worst-case model<=40 1.00(HR)>=60 0.26(HR) |
| Alibhai | 2010 | Age, Sex, CD4, Marital status, Education, Occupation,  | - | 0.95 (HR)2 | - | - | - | - | - | Education: None 1.00 (HR) Primary 0.42(HR) |
| Palombi | 2009 | BMI, CD4, Clinical staging, Hb, Age, Sex, Adherence, Calendar year | Model 1: 0.91(HR)3Model 2: 0.92(HR) | Model 1: 0.80 (HR)4Model 2: 0.84 (HR) | Model 2:Stage 1/2 1.00(HR)Stage 3/4 1.78(HR) | Model 1: 0.79 (HR)5Model 2: 0.80 (HR) | -- | -- | 6Model 1:M 1.00 (HR)F 0.51(HR)Model 2:M 1.00 (HR)F 0.45 (HR) | Model 1:Attendance to visits > 95% 0.74 (HR)7Model 2:Calendar year, per 1yr increase 0.87 (HR) |
| Abaasa | 2008 | Age, Sex, Education, Adherence | - | - | - | - | - | - | - | Adherence > 95 % 0.46 (HR)Any education 0.67 (HR) |
| De Beaudrap | 2008 | BMI, CD4, TLC | Model 1: 0.84(HR)3Model 2: 0.82(HR) | Model 1: 0.87 (HR)8 | - | - | - | - | - | TLC per 200cells/μl increment 0.80 (HR) |
| Bisson | 2008 | CD4, Hb, Sex | - | >100 1.00 (HR)50-99 2.51 (HR)<50 3.86 (HR) | - | - | - | - | F 1.00 (HR)M 1.74 (HR) | - |
| Johannessen | 2008 | BMI, Clinical staging, Hb, Sex, TLC , ART start year, Platelet count | >18.5 1.00 (HR)<16 2.12 (HR) | - | - | >12(F) 1.00(HR)>13(M)1.00(HR)8-9.9 7.50(HR)<8 9.20(HR)  | - | - | - | Platelet count:>150x109/L 1.00 (HR)  <150x109/L 2.30 (HR)ART start year : 2003-04 1.00 (HR) 2005-06 0.40 (HR) |
| Laurent | 2008 | CD4 | - | >50 1.00 (HR)<50 5.69 (HR) | - | - | - | - | - | - |
| MacPherson | 2008 | Weight , CD4, Clinical Staging , Sex | > 45kg 1.00 (HR)<45kg 2.48 (HR) | >50 1.00 (HR)<50 2.90 (HR) | Stage 1/2 1.00(HR)Stage 3/4 1.59(HR) | - | - | - | F 1.00 (HR)M 1.62 (HR) | - |
| **Study** | **Year** | **Variables Assessed** | **Strength of Association (Measure of AssociationΩ)** |
|  |  |  | **BMI** | **BaselineCD4 Count cells/mm3** | **Clinical Staging** | **Hb** | **Age** | **HIV–1RNA Plasma Concentration** | **Sex** | **Others** |
| Mulenga9 | 2008 | Creatinine clearance | - | - | - | - | - | - | - | Creatinine clearance:Normal 1.00 (HR); Mildly reduced 1.70(HR); Moderately reduced 2.30 (HR); Severely reduced 4.30 (HR) |
| Toure | 2008 | BMI, CD4, Clinical staging,Hb, Sex | >25 1.00 (HR)18.5-25 0.93 (HR) <18.5 193(HR) | >150 1.00 (HR)101-150 1.32 (HR) 51-100 1.63 (HR)<50 2.72(HR) | Stage1/2 1.00(HR)Stage 3/4 1.61(HR) | >10 1.00(HR)<10 1.22(HR) | - | - | F 1.00 (HR)M 1.52 (HR) | - |
| Karcher | 2007 | Clinical staging, Age, Adherence | - | - | No AIDS 1.00(HR)AIDS 5.83(HR) | - | 1.06 (HR)10 | - | - | Adherence 2months11 1.05 (HR) |
| Lowrance | 2007 | CD4, Clinical staging, Age, Sex, CTX prophylaxis,TB | - | - | Stage 3 1.00(HR)Stage 4 1.99(HR) | - | - | - | F 1.00 (HR)M 1.54 (HR) | Non-CTX site 1.00 (HR)CTX site 0.62 (HR) |
| Etard | 2006 | BMI, CD4, Hb | < 19 1.00 (HR)>19 0.54 (HR) | < 200 1.00 (HR)> 200 0.43 (HR) | - | < 10 1.00 (HR)> 10 0.56 (HR) | - | - | - | - |
| Ferradini | 2006 | BMI, CD4 , Clinical staging, Sex, | >18.5 1.00 (HR)<18.5 2.92 (HR) | >50 1.00 (HR)<50 1.64 (HR) | - | - | - | - |  F 1.00 (HR)M 1.63 (HR) | - |
| Jerene | 2006 | Clinical staging, TLC | - | - | Stage2/3 1.00(HR)Stage 4 2.40(HR) | - | - | - | - | TLC : >750 1.00 (HR)<750 3.60 (HR) |
| Lawn | 2006 | CD4,Clinical staging, Age, Viral load, Sex | - | 0.62 (HR)12, 13 | Stage1/2/3 1.00(HR)Stage4 2.78(HR)13 | - | - | - | F 1.00 (HR)M 2.00(HR)13 | CD4 count at 4 months: 0.42 (HR)12, 14 |
| Stringer | 2006 | BMI, CD4,Clinical staging,Hb,Adherence | >16 1.00 (HR)<16 2.40 (HR) | >200 1.00 (HR)50-199 1.40 (HR)<50 2.20 (HR) | Stage1/2 1.00(HR)Stage 3 1.80(HR)Stage 4 2.90(HR) | >8 1.00(HR)<8 3.10(HR) | - | - | - | Non – adherence:<90th percentile 1.00 (HR) >90th percentile 2.90 (HR) |
| Coetzee | 2004 | CD4, KS | - | 2·41 (HR)12 | - | - | - | - | - | Kaposi sarcoma 4.82 (HR) |
| Djomand | 2003 | CD4, Clinical Staging | - | >50 1.00 (HR)<50 5.90 (HR) | Stage 1/2 1.00(HR)Stage 3/4 3.20(HR) | - | - | - | - | - |
| **Asia** |  |  |  |  |  |  |  |  |  |  |
| Chasombat | 2009 | Weight, CD4, Clinical staging, Age, Sex, Hospital type | >60kgs 1.00 (HR)50-59 1.53 (HR)40-49 2.75 (HR)<40 6.29 (HR) | >200 1.00 (HR)50-99 1.61 (HR)<50 2.43 (HR) | Asymptomatic 1.00(HR) Symptomatic 1.41(HR) AIDS 1.75(HR) | - | 15-29 1.00 (HR)>40 1.24 (HR) | - | F 1.00 (HR)M 1.96 (HR) | Hospital Type:District/Community 1.00 (HR)private 0.63 (HR)university 0.70 (HR)regional 0.70 (HR)province/general 0.86 (HR) |
|  |  |  |  |  |  |  |  |  |  |  |
| **Study** | **Year** | **Variables Assessed** | **Strength of Association (Measure of AssociationΩ)** |
|  |  |  | **BMI** | **BaselineCD4 Count cells/mm3** | **Clinical Staging** | **Hb** | **Age** | **HIV–1RNA Plasma Concentration** | **Sex** | **Others** |
| Madec | 2007 | BMI, CD4, Clinical staging, Age, HAART discontinuation, CTX prophylaxis, Fluconazole prophylaxis | >18.5 1.00 (HR)<17 2.47(HR) | >100 1.00 (HR)20-50 2.78 (HR)<20 8.93 (HR) | Stage3 1.00(HR)Stage 4 1.86(HR) | - | 30-45 1.00 (HR)>45 1.83 (HR) | - | - | HAART discontinuation >1month:No 1.00 (HR)Yes 3.23 (HR)CTX prophylaxis: No 1.00 (HR) Yes 0.15 (HR)Fluconazole prophylaxis: No 1.00 (HR) Yes 0.50 (HR |
| **Americas** |  |  |  |  |  |  |  |  |  |  |
| Severe | 2005 | Weight , CD4, Clinical staging,  | 3.30 (HR)15 | >50 1.00 (HR)<50 1.60 (HR) | No AIDS 1.00 (HR)AIDS 2.10 (HR) | - | - | - | - |  - |
| **Multi -Regional** |  |  |  |  |  |  |  |  |  |  |
| Tuboi | 2009 | CD4, Clinical staging, Age (per ten years) | - | 16100vs.50 0.79(HR)200vs.50 0.58(HR)350vs.50 0.43(HR) | No AIDS 1.00(HR) AIDS 3.10(HR) | - | 1.12(HR)17 | - | - | - |
| Brinkhof | 2008 | CD418, Clinical staging19, Treatment access, Follow-up | - | >50 1.00(HR)<25 3.34(HR) | Stage 1/2 1.00(HR)Stage 3/4 5.35(HR) | - | - | - | - | Treatment access: Free 1.00 (HR) Fee 4.64 (HR)Follow-up: passive follow-up 1.00 (HR) active follow-up 5.15 (HR)  |
| Braitstein | 2006 | CD4, Clinical staging, Age, Sex, ART regimen, Free access to treatment, Use of generic drugs, Routine monitoring of virological response, TB clinic on site | - | <25 1.00(HR)100-199 0.37(HR)200-349 0.14(HR)>=350 0.34(HR) | Stage 1/2 1.00 (HR)Stage 3/4 2.02 (HR)  | - | - | - | - | Free access to treatment: No 1.00 (HR) Yes 0.25 (HR)TB clinic on site: No 1.00 (HR) Yes 3.76 (HR)  |
| Calmy | 2006 | BMI, CD4, Clinical Staging,Hb, Sex | >18 1.00(HR)<18 2.38(HR) | >200 1.00(HR)15-49 2.54(HR)<15 3.63(HR) | Stage 1/2 1.00(HR)Stage 3 2.07(HR)Stage 4 3.86(HR) | >10 1.00(HR)8-9 1.48(HR)<8 2.62(HR) | - | - | F 1.00(HR)M 1.75(HR) | - |
| **Odds Ratio(OR)** |
| **Africa** |  |  |  |  |  |  |  |  |  |  |
| Marazzi | 2008 | BMI, CD4, Clinical staging, Hb, Age, Sex, Viral load | >20 1.00 (OR)18-20 1.59 (OR) <18 4.87 (OR) | >200 1.00 (OR)<200 1.70 (OR) | Stage 1/2 1.00 (OR)Stage 3/4 1.73 (OR) | >10 1.00 (OR)8-10 1.51 (OR)<8 2.10 (OR) | 1.03 (OR)10 | <4 1.00 (OR)4-5 2.15(OR)>5 2.00 (OR) | - |  |
|  |  |  |  |
| **Study** | **Year** | **Variables Assessed** | **Strength of Association (Measure of AssociationΩ)** |
|  |  |  | **BMI** | **BaselineCD4 Count cells/mm3** | **Clinical Staging** | **Hb** | **Age** | **HIV–1RNA Plasma Concentration** | **Sex** | **Others** |
| Zachariah | 2006 | BMI,CD4, Clinical stage | >18.5 1.00 (OR) 17-18.4 2.10 (OR)16-16.9 2.40 (OR) <15.9 6.00 (OR)  | >200 1.00 (OR)<50 2.20(OR) | Stage 3 1.00 (OR)Stage 4 2.10 (OR) | - | - | - | - |  |
| Weidle | 2002 | CD4, Viral load | - | >50 1.00 (OR)<50 2.93 (OR) | - | - | - | - | - |  |

**Legend & Footnotes: Ω** only those measures of association reaching statistical significance in multivariate analysis are included; **BMI**= Body Mass Index. All BMI values are baseline and in kg/m2 unless mentioned otherwise; **CD4**= CD4 cell count. All CD4 counts are baseline and in cells/mm3 unless mentioned otherwise; **Clinical staging=** World Health Organization (WHO) Clinical staging unless mentioned otherwise; **Hb**= Hemoglobin, Hemoglobin values are baseline and in gm/dL unless mentioned otherwise; **Age** is in years unless mentioned otherwise; **Viral Load**= HIV–1RNA plasma concentration, Viral load is in log copies/ml unless mentioned otherwise; **TLC**= Total leukocyte count, TLC is cells/mL unless mentioned otherwise; **CTX site**= Cotrimoxazole treatment site; **TB**= Tuberculosis; **KS**= Kaposi’s Sarcoma; **ART**= Anti-retroviral therapy; **HAART**= Highly active antiretroviral therapy; **F**= Female; **M**= Male;

1Real-case model used mortality data observed and worst-case model assumed those who were lost to follow-up were dead;2Change in Hazard ratio/Odds ratio for every 10 cells/mm3 increase in CD4 cell count;3Change in Hazard ratio/Odds ratio for every unit increment in BMI;4 Change in Hazard ratio/Odds ratio for every100 cells/mm3 increase in CD4 cell count;5 Change in Hazard ratio/Odds ratio for every 1gm/dl increase in Hb concentration;6Hazard ratios can be converted to F 1.00 M 1.96 in model 1 and F 1.00 M 2.22 in model 2; 7Adherence described by participants who attended >95% of their drug pickup appointments;8Change in Hazard ratio/Odds ratio for every 25cells/mm3 increase in CD4 cell count; 9For mortality at or before 90 days of therapy; 10Change in Hazard ratio/Odds ratio for every unit increase in age; 11Mean Cumulative Adherence after 2 months of therapy; 12Analyzed in50 cells/mm3 increments;13For early deaths (<4 months post –HAART);14For late deaths(>4 months post–HAART); 15For men <48.9kg and for women <43kg; 16Hazard ratios can be converted to 50 vs 100: 1.27(HR); 50 vs 200: 1.72(HR); 50 vs 350: 2.33(HR)17Change in hazard ratio/odds ratio for every 10 years increment in age;18Not measured in1404 participants; 19Not performed in 1004 participant